Masiello SA. 2002. Your request to supplement your BLA to include Hollister-Stier Laboratories LLC, Spokane, Washington, as a contract manufacturer has been approved. Letter to Giri L, BioPort Corporation, Lansing, Mich.

McGann VG, Stearman RL, Wright GG. 1961. Studies on immunity in anthrax. VIII. Relationship of complement-fixing activity to protective activity of culture filtrates. Journal of Immunology 86:458–464.

Michigan Biologic Products Institute. 1997–1998. Strategic Plans and Updates. Lansing, Mich.: BioPort Corporation.

Myers R. 2001. Technical review. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., December 15.

Myers R. 2002a. Follow-up questions. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., January 9.

Myers R. 2002b. Timeline for vaccine manufacture. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., February 19.

Myers R, Winberry L, Park S. 2001. Components of the Anthrax Vaccine Adsorbed and contrast with Merck vaccine. Presentation to the Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Meeting II, Washington, D.C.

Parkman PD, Hardegree MC. 1999. Regulation and testing of vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines, 3rd ed. Philadelphia, Pa.: W.B. Saunders Company. Pp. 1131–1143.

Pittman M. 1969. Michigan Department of Health: application for license for anthrax vaccine. Memorandum to Gibson ST, Department of Health, Education, and Welfare, Washington, D.C.

Pittman PR. 2001. Anthrax vaccine: dose reduction/route change pilot study. Presentation to the Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Meeting II, Washington, D.C.

Pittman PR, Kim-Ahn G, Pifat DY, Coon K, Gibbs P, Little S, Pace-Templeton J, Myers R, Parker GW, Friedlander AM. 2002. Anthrax vaccine: safety and immunogenicity of a dose-reduction, route comparison study in humans. Vaccine 20(9–10):1412–1420.

Puziss M, Wright GG. 1954. Studies on immunity in anthrax. IV. Factors influencing elaboration of the protective antigen of Bacillus anthracis in chemically defined media. Journal of Bacteriology 68:474–482.

Puziss M, Wright GG. 1963. Studies on immunity in anthrax. X. Gel adsorbed protective antigen for immunization of man. Journal of Bacteriology 85:230–236.

Puziss M, Manning LC, Lynch JW, Barclay E, Abelow I, Wright GG. 1963. Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. Applied Microbiology 11(4):330–334.


Turnbull PCB. 2000. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Current Opinion in Infectious Diseases 13(2):113–120.


Winberry LK, Bondoc L, Park S, Simon L, Shih CN, Giri L. 2001. Characterization of the US-licensed anthrax vaccine. In: Program and Abstracts Book of the Fourth Annual Conference on Anthrax. Washington, D.C.: American Society for Microbiology.

Wright GG, Puziss M. 1957. Elaboration of protective antigen of Bacillus anthracis under anaerobic conditions. Nature 179:916–917.

Wright GG, Hedberg MA, Slein JB. 1954. Studies on immunity in anthrax. III. Elaboration of protective antigen in a chemically-defined, non-protein medium. Journal of Immunology 72:263–269.

Wright GG, Puziss M, Neely WB. 1962. Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis. Journal of Immunology 83:515–522.


Zoon KC. 1997. Inspections of Michigan Biologic Products Institute, November 18 and 27, 1996. Letter to Myers R, Michigan Biologic Products Institute, Lansing, Mich.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement